| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Enhanced Group Inc.
13D/A
ENHA · 29333R107
|
34.3% |
9/21/2026
Event 9/17/2026
|
||||
| Apeiron Investment Group Ltd. | 34.3% | |||||
| Enhanced Holdings LP | 34.3% | |||||
| Enhanced Holdings GP | 34.3% | |||||
| Christian Angermayer | 34.3% | |||||
|
AtaiBeckley Inc.
13D/A
ATAI · 04650F101
|
0% |
9/14/2026
Event 9/11/2026
|
||||
| Apeiron Investment Group Ltd. | 0% | |||||
| Apeiron Presight Capital Fund II, L.P. | 0% | |||||
| Presight Capital Management I, L.L.C. | 0% | |||||
| Fabian Hansen | 0% | |||||
| Christian Angermayer | 0% | |||||
|
ATAI Life Sciences N.V.
13D/A
IGXT · 45822R101
|
24.0% |
10/20/2025
Event 10/16/2025
|
||||
| Apeiron Investment Group Ltd. | 23.4% | |||||
| Apeiron Presight Capital Fund II, L.P. | 0.8% | |||||
| Presight Capital Management I, L.L.C. | 0.8% | |||||
| Fabian Hansen | 0.8% | |||||
| Christian Angermayer | 24.0% | |||||
|
Neuphoria Therapeutics Inc.
13D/A
NEUP · 64136E102
|
4.5% |
1/28/2025
Event 1/24/2025
|
||||
| Apeiron Investment Group Ltd. | 4.5% | |||||
| Apeiron Presight Capital Fund II, L.P. | 0% | |||||
| Presight Capital Management I, L.L.C. | 0% | |||||
| Fabian Hansen | 0% | |||||
| Christian Angermayer | 4.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.